Latest revenue
$3.0M
as of 2026-03-31
Latest net income
$-73.3M
as of 2026-03-31
Net margin
-2443.0%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $2.59B
- Enterprise value
- $2.59B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $17.32
- 52-wk low
- $2.83
- Beta
- —
- Shares out
- 191.6M
5-year trend
What this company does
Item 1. Business. Overview We are a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients living with cancer and genetic disease. Our Dynamo® platform integrates an array of leading-edge computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. Precision medicine emerged as an approach for disease treatment as the understanding of the link between genetic alterations, protein dysfunction and diseases evolved. Precision medicine aims to specifically and potently drug genetically validated target proteins (i.e., genetic variants potentially…
AI summary unavailable — showing raw filing excerpt
Generated from RLAY's filing dated 2026-02-26
Key risks
Item 1A. Risk Factors. Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes and "Management’s Discussion and Analysis of Financial Condition and Results of Operations," before deciding whether to invest in our common stock. We believe the risks described below include risks that are material to us as well as other risks that may adversely affect our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could…
AI summary unavailable — showing raw filing excerpt
Generated from RLAY's filing dated 2026-02-26
Profitability
Operating margin
-1971.6%
47.0%Net margin
-1800.6%
46.6%Return on equity
-48.8%
12.3%Return on assets
-44.5%
14.8%Leverage
Debt / equity
0.10×
20.4%Debt / assets
8.7%
18.6%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $3.0M | -60.9% | $-73.3M | +4.9% | -2443.0% |
Q4 2025 2025-12-31 | $7.0M | — | $-54.9M | +27.8% | -784.3% |
Q3 2025 2025-09-30 | $0 | — | $-74.1M | +15.8% | — |
Q2 2025 2025-06-30 | $677.0K | — | $-70.4M | +23.7% | -10395.1% |
Q1 2025 2025-03-31 | $7.7M | -23.3% | $-77.1M | +5.3% | -1003.6% |
Q4 2024 2024-12-31 | $0 | — | $-76.0M | — | — |
Q3 2024 2024-09-30 | $0 | -100.0% | $-88.1M | -34.0% | — |
Q2 2024 2024-06-30 | $0 | -100.0% | $-92.2M | +6.4% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Biological Products, (No Diagnostic Substances) · SIC 2836
Your notes
Keep private notes on RLAY — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$3.1M
Net activity
−$3.1M
Distinct insiders
5
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns RLAY
Institutional value
$358.8M
Total shares held
37.1M
Distinct holders
121
-102 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 13.0M | $129.1M | -253.2K (-1.9%) | Trimmed |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 7.4M | $73.5M | — | New |
| 3 | DIMENSIONAL FUND ADVISORS LP | 2.9M | $29.2M | +460.2K (+18.6%) | Added |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1.9M | $18.5M | — | New |
| 5 | Alphabet Inc. | 1.6M | $15.6M | -4.6K (-0.3%) | Trimmed |
| 6 | VANGUARD FIDUCIARY TRUST CO | 900.5K | $9.0M | — | New |
| 7 | Connor, Clark & Lunn Investment Management Ltd. | 837.0K | $8.3M | +447.5K (+114.9%) | Added |
| 8 | Invesco Ltd. | 669.9K | $6.7M | -195.6K (-22.6%) | Trimmed |
| 9 | CONGRESS ASSET MANAGEMENT CO | 618.9K | $6.2M | +204.8K (+49.4%) | Added |
| 10 | JPMORGAN CHASE & CO | 647.5K | $6.1M | +221.6K (+52.0%) | Added |
| 11 | UBS Group AG | 527.6K | $5.2M | +231.6K (+78.2%) | Added |
| 12 | JANE STREET GROUP, LLC | 423.5K | $4.2M | +347.1K (+453.8%) | Added |
| 13 | Bank of New York Mellon Corp | 382.9K | $3.8M | +4.2K (+1.1%) | Added |
| 14 | Hudson Bay Capital Management LP | 311.3K | $3.1M | -140.2K (-31.0%) | Trimmed |
| 15 | Nuveen, LLC | 302.2K | $3.0M | +1.7K (+0.6%) | Added |
| 16 | Swiss National Bank | 238.0K | $2.4M | +0 (+0.0%) | No change |
| 17 | RHUMBLINE ADVISERS | 216.9K | $2.2M | +1.2K (+0.6%) | Added |
| 18 | Voya Investment Management LLC | 216.1K | $2.1M | +191.5K (+779.2%) | Added |
| 19 | TD ASSET MANAGEMENT INC | 214.2K | $2.1M | +32.2K (+17.7%) | Added |
| 20 | UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | 210.5K | $2.1M | +620 (+0.3%) | Added |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once RLAY's latest filing finishes processing.